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ABSTRACT 
 
Angiotensin-converting enzyme (ACE) inhibitors including quinapril could exert a protective effect on 
cardiovascular system through endothelial system in normoglycemic and diabetic rats. The present 
experimental work was designed to study the vascular reactivity of aortic ring segments isolated from 
streptozotocin (STZ)-diabetic rats treated for 4 weeks with nitro-L-arginine-methyl ester (L-NAME; 
50 mg/100 ml) or L-NAME plus quinapril (10 mg/100 ml) in drinking water. The results showed that 
quinapril treatment significantly attenuated the augmented contractile response to phenylephrine and 
KCl in diabetic rats. In addition, quinapril treatment partially restored the reduced contractile 
response in diabetic animals treated chronically with L-NAME. It can be concluded that quinapril 
could partly counteract the effect of long-term L-NAME administration on vascular reactivity in STZ-
diabetic rats.  Iran. Biomed. J. 9 (1): 33-36, 2005  
 
Keywords: Quinapril, Nitric oxide, Aortic reactivity, Diabetes mellitus, Streptozotocin (STZ) 
 
 
INTRODUCTION 
 
A ngiotensin-converting enzyme (ACE) inhibitors including quinapril exert some beneficial and protective effects on 
cardiovascular system through improving 
endothelial ability to release vasorelaxant agents 
[1]. It has previously been reported that quinapril 
inhibits the contractile and presser effects of 
angiotensin I in rat aorta and lowers blood pressure 
in both high- and normal-renin rodent and diuretic-
treated dog models of hypertension [2]. 
Furthermore, quinapril treatment appears to be an 
effective anti-hypertensive drug devoid of 
undesirable effects on metabolic risk factors for 
cardiovascular disease [3]. Quinapril also produces 
favorable hemodynamic changes and may improve 
ventricular and endothelial function in patients with 
various cardiovascular disorders [4]. Although ACE 
inhibitors like quinapril have been shown to 
enhance conduit artery endothelial function in 
animals and in patients with established coronary 
atherosclerosis, their precise mechanism of effect 
on vascular system in insulin-dependent diabetes 
mellitus has not been well established [5]. Since the 
attenuating effect of quinapril on phenylephrine 
(PE)-induced contractile responsiveness of aortic 
rings has previously been reported in streptozotocin 
(STZ)-diabetic rats [6], this study was undertaken to 
investigate the effect of quinapril on the reactivity 
of thoracic aorta in STZ-diabetic rats following 
chronic administration of nitro-L-arginine-methyl 
ester (L-NAME).  
 
 
MATERIALS AND METHODS 
 
Animals.  Male Albino Wistar rats, weighing 230-
275 g and 8-10 weeks old, were obtained from the 
Pasteur institute of Iran (Tehran) and housed in an 
air-conditioned colony room on a light/dark cycle at 
21 ± 2°C and then were supplied with standard rat 
chow and tap water ad libitum. The animals were 
randomly divided into five experimental groups: 
control (n = 8), untreated diabetic (n = 7), quinapril-
treated diabetic (QD, n = 6), L-NAME-treated 
diabetic (LD, n = 6) and quanipril plus L-NAME-
treated diabetic groups (QDL, n = 10). Diabetes was 
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induced by a single intraperitoneal injection of STZ 
(60 mg/kg) and dissolved in cold 0.9% saline 
immediately before use. Inhibitor of nitric oxide 
(NO) synthesis (L-NAME) was given in drinking 
water for 4 weeks at a concentration of 50 mg/100 
ml of tap water. Other rats were given L-NAME (50 
mg/100 ml) plus quinapril (10 mg/100 ml). All of 
the experimental groups received the treatments for 
a period of 4 weeks. Serum glucose level and body 
weight were monitored at the start and the end of 
the experiment. Diabetes was verified by a serum 
glucose level higher than 250 mg/dl using glucose 
oxidation method (glucose oxidase kit, Zistchimie, 
Tehran, Iran).  
 
Experimental protocol.  At the end of the 
experiment, the rats were anesthetized with diethyl 
ether and decapitated. Then, after opening the 
abdomen, descending thoracic aorta was carefully 
excised and placed in a Petri dish filled with cold 
Krebs solution containing (in mM): NaCl, 118.5; 
KCl, 4.74; CaCl2, 2.5; MgSO4, 1.18; KH2PO4, 1.18; 
NaHCO3, 24.9 and glucose, 10.0. The aorta was 
cleaned of excess connective tissue and fat and cut 
into rings of approximately 4 mm in length. Aortic 
rings were suspended between the bases of two 
triangular-shaped wires. One wire was attached to a 
fixed tissue support in a 50-ml isolated tissue bath 
containing Krebs solution (pH 7.4) maintained at 
37°C and continuously aerated with a mixture of 
5% CO2 and 95% O2. The other end of each wire 
was attached by a cotton thread to a F60 isometric 
force transducer connected to MK-IV-P 
physiograph (Narco Biosystems, USA). In all 
experiments, special care was taken to avoid 
damaging the luminal surface of endothelium. The 
rings were allowed to equilibrate for 90 min under a 
resting tension of 2 g before experiments were 
begun. In preliminary experiments, this had been 
shown to be the optimal resting tension for all 
groups. During equilibration period, the rings were 
washed every 30 min. For examining the 
endothelial integrity, pre-constricted rings with 
phenylephrine (PE, 1 µM) were exposed to a single 
addition of acetylcholine (ACh, 10 µM). Only those 
endo-thelium-intact rings exhibiting more than 50% 
relaxation in response to ACh were used for further 
experiments. In all experiments, after addition of 
each dose, a plateau response was obtained before 
addition of a subsequent dose. After an initial 
equilibration, the aortic rings were allowed to 
achieve maximal tension by cumulative addition of 
KCl (10-50 mM) or phenylephrine (10-9-10-5 M) to 
the bath solution.  
 
Drugs and chemicals.  Phenylephrine-HCl was 
obtained from Darupakhsh Co. (Tehran, Iran).  
L-NAME and STZ were purchased from Sigma 
Chemical (St. Louis, Mo., USA). All other 
chemicals were purchased from Merck (Germany). 
All drugs except STZ were dissolved in Krebs’ 
solution. STZ was freshly dissolved in 0.9% saline 
solution.  
 
Data and statistical analysis.  All values were 
given as mean ± SEM. Contractile response to PE 
and KCl was expressed as grams of tension (g). 
Statistical analysis was carried out using student’s 
paired t-test and one-way analysis of variance 
(ANOVA) followed by Tukey post-hoc test. 
Statistical P<0.05 was considered significant. 
 
 
RESULTS 
 
Phenylephrine (10-9-10-5 M) induced a 
concentration-dependent contraction of the aortic 
rings of all experimental groups with a peak tension 
of 1.12 ± 0.05, 1.44 ± 0.06, 1.01 ± 0.07, 1.27 ± 
0.06, and 1.17± 0.06 g in the control, diabetic, LD, 
QD, and QDL groups, respectively (Fig. 1A). In this 
respect, the existing differences between control 
and diabetic and between diabetic and QD groups 
were statistically significant (P<0.01 and P<0.05 
respectively). In addition, chronic administration of 
L-NAME in diabetic group caused a marked 
significant reduction in contractile response of 
aortic rings as compared to untreated diabetic group 
at PE concentrations higher than 10-7 M (P<0.005). 
Meanwhile, co-administration of quinapril and L-
NAME in QDL group partially restored the 
attenuated contractile response to the level of 
quinapril-treated diabetic group at PE 
concentrations greater than 10-7 M.  
Addition of KCl (10-50 mM) caused a dose-
dependent contraction of the aortic rings in all of 
the experimental groups (Fig. 1B). In this regard, 
the existing differences between control and 
diabetic and between diabetic and QD groups were 
also statistically significant (P<0.005 and P<0.05, 
respectively). Furthermore, chronic administration 
of L-NAME in diabetic group caused a very marked 
significant attenuation of contractile response of 
aortic rings as compared to untreated diabetic group 
at KCl concentrations higher than 30 mM 
(P<0.001). On the other hand, co-administration of 
quinapril and L-NAME in QDL group partially 
restored this attenuated contractile response to the 
level of the quinapril-treated diabetic group at KCl 
concentrations greater than 20 mM.  
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Fig. 1. Cumulative concentration-response curves for 
phenylephrine (A) and KCl (B) in aortic preparations four 
weeks after experiment. Contractile responses are expressed as 
grams of tension (g).  Data have been shown as means ± S.E.M. 
 
 
 
Table 1 presents the body weight, serum glucose 
level, and maximum contractile force following 
KCl and PE application in the experimental groups. 
Regarding body weight, there was no significant 
differences among the groups before the 
experiment. In diabetic group, there was a 
significant reduction in  body  weight  4 weeks after  
 
 
the experiment in comparison with data before the 
study (P<0.01). Meanwhile, quinapril and L-NAME 
treatment individually or in combination did not 
significantly attenuate this reduction. Regarding 
serum glucose, there was also no significant 
differences among the groups before the 
experiment. In diabetic group, there was a 
significant increase in serum glucose 4 weeks after 
the experiment in comparison with data before the 
study (P<0.001). It was noteworthy that quinapril 
and L-NAME treatment individually or in 
combination did not significantly attenuate this 
increase in serum glucose.  
 
 
DISCUSSION 
 
The present study provides evidence that chronic 
quinapril treatment of STZ-diabetic rats could 
significantly attenuate the enhanced reactivity of 
isolated aortic rings in response to general and 
specific vasoconstrictors including KCl and PE. 
Meanwhile, chronic quinapril treatment caused a 
partial reversal of the reduced contractile response 
in L-NAME-treated diabetic group.  
Although the actual responsible mechanisms for 
increased reactivity of aorta in diabetic state have 
not completely been understood, some possible 
factors that could have been involved in the in-
creased vascular smooth muscle responsiveness to 
α1-adrenoceptor agonist in diabetic rats are deficient 
endothelial activity, enhanced phosphoinositide (PI) 
metabolism, enhanced sensitivity of calcium 
channels, increased sensitivity to adrenergic 
agonists and enhanced oxidative stress due to 
excessive production of oxygen-free radicals and 
decreased antioxidant defense systems. Therefore, 
the oxidative stress in diabetic animals might be 
responsible for augmented contractility together 
with deficient endothelial activity [7-8].  
Table 1. Body weight, serum glucose level, and maximum contractile force following KCl and PE in control and diabetic groups. 
Parameter Control Diabetic Quinapril-treated diabetic 
L-NAME-treated 
diabetic 
Quinapril plus L-NAME-
treated diabetic 
Body weight (g) 
    Before the experiment 
    After the experiment 
 
 
257.12 ±   9.17 
301.28 ± 12.31 
 
261.19 ± 13.10 
207.21 ± 12.08 
 
249.78 ± 10.09 
205.14 ± 13.45 
 
251.32 ± 12.17 
198.21 ±   9.14 
 
251.05 ± 11.98 
212.14 ± 10.73 
Serum Glucose (mg/dl) 
    Before the experiment 
    After the experiment 
 
 
116.21 ± 6.08 
132.27 ± 7.79 
 
131.22 ±   5.98 
412.23 ± 20.18 
 
98.12 ±   9.07 
402.73 ± 15.64 
 
127.83 ± 10.11 
387.12 ± 19.54 
 
132.73 ±   8.06 
396.23 ± 21.32 
Maximum Contractile Force (g) 
    K+ (50 mM) 
    PE (10-5 M) 
 
0.76 ± 0.05 
1.12 ± 0.05 
 
0.97 ± 0.04 
1.44 ± 0.06 
 
0.63 ± 0.03 
1.01 ± 0.07 
 
0.87 ± 0.05 
1.27 ± 0.06 
 
0.84 ± 0.04 
1.17 ± 0.06 
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In this study, chronic L-NAME administration to 
diabetic rats unexpectedly induced a reduction in 
contractile response to vasoconstrictors that was 
partly prevented by the angiotensin converting 
enzyme inhibitor quinapril. The reduced contractile 
response in L-NAME-treated diabetic group may be 
associated with a decreased vascular reactivity of 
the aorta in vitro to exogenously added 
phenylephrine and KCl, and drugs acting beyond 
receptor activation. In this respect, it has previously 
been demonstrated that consequences of acute NO 
blockade differs from chronic NO blockade with L-
NAME. Acute L-NAME administration was 
associated with an increased vascular reactivity in 
vitro, whereas chronic L-NAME treatment induced 
a hyporeactivity to the same stimulus in the same 
vessel in vitro [9].  
Chronic NO blockade might also induce a down 
regulation by chronic hyperstimulation of the 
contractile signaling pathways in aortic smooth 
muscle cells. This would be a response to an 
increased endogenous tonic contractile state in 
response to a normal level of contractile agonists, as 
previously shown [10-12]. This is supported by the 
observations that either angiotensin converting 
enzyme inhibitor or angiotensin receptor blockers 
can prevent L-NAME-induced hypertension [13-
14]. Thus, multiple pathways might be triggered in 
response to chronic NO synthase inhibition. Further 
investigations are certainly needed to elucidate the 
mechanism or mechanisms involved in L-NAME–
induced hyporeactivity. 
In summary, the results demonstrated that chronic 
NO inhibition could decrease the contractile 
responsiveness of aortic rings from STZ-diabetic 
rats and chronic quinapril treatment could partially 
reverse this response. 
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